Rep. Gilbert Ray Cisneros, Jr. Buys Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Cytokinetics, Incorporated (NASDAQ:CYTK). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Cytokinetics stock on September 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Alkermes (NASDAQ:ALKS) on 9/29/2026.

Cytokinetics Stock Up 2.9%

CYTK stock opened at $63.43 on Thursday. The company has a market cap of $7.89 billion, a PE ratio of -8.79 and a beta of 0.41. The business has a 50-day simple moving average of $70.83 and a 200 day simple moving average of $73.27. Cytokinetics, Incorporated has a 52 week low of $54.30 and a 52 week high of $88.31.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.63) by $0.13. The firm had revenue of $28.62 million for the quarter, compared to analyst estimates of $17.59 million. During the same quarter in the previous year, the company earned ($1.12) earnings per share. The company’s quarterly revenue was down 57.1% on a year-over-year basis. On average, analysts anticipate that Cytokinetics, Incorporated will post -5.98 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Needham & Company LLC upped their price target on shares of Cytokinetics from $102.00 to $112.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Royal Bank Of Canada lifted their price objective on shares of Cytokinetics from $112.00 to $113.00 and gave the company an “outperform” rating in a research note on Thursday, October 8th. HC Wainwright restated a “buy” rating and set a $140.00 target price on shares of Cytokinetics in a research note on Monday, August 31st. Mizuho upped their target price on Cytokinetics from $100.00 to $118.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 24th. Finally, JPMorgan Chase & Co. raised their target price on Cytokinetics from $97.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. Eighteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Cytokinetics currently has an average rating of “Moderate Buy” and an average price target of $105.44.

Insider Activity

In related news, CEO Robert Blum sold 97,926 shares of Cytokinetics stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $69.33, for a total transaction of $6,789,209.58. Following the sale, the chief executive officer directly owned 385,320 shares in the company, valued at $26,714,235.60. This trade represents a 20.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director B. Parshall sold 5,000 shares of the firm’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $71.48, for a total transaction of $357,400.00. Following the transaction, the director directly owned 10,784 shares of the company’s stock, valued at $770,840.32. The trade was a 31.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 191,426 shares of company stock valued at $13,601,885 over the last quarter. 2.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CYTK. Principal Financial Group Inc. increased its holdings in Cytokinetics by 11.9% in the 1st quarter. Principal Financial Group Inc. now owns 1,093,485 shares of the biopharmaceutical company’s stock worth $72,072,000 after purchasing an additional 116,593 shares in the last quarter. Frazier Life Sciences Management L.P. boosted its stake in shares of Cytokinetics by 5.0% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 934,642 shares of the biopharmaceutical company’s stock valued at $59,387,000 after purchasing an additional 44,197 shares in the last quarter. ADAR1 Capital Management LLC boosted its stake in shares of Cytokinetics by 17.1% during the first quarter. ADAR1 Capital Management LLC now owns 632,556 shares of the biopharmaceutical company’s stock valued at $41,692,000 after purchasing an additional 92,390 shares in the last quarter. Siren L.L.C. bought a new stake in shares of Cytokinetics during the first quarter worth about $40,466,000. Finally, Handelsbanken Fonder AB grew its holdings in shares of Cytokinetics by 63.8% during the second quarter. Handelsbanken Fonder AB now owns 405,000 shares of the biopharmaceutical company’s stock worth $34,502,000 after purchasing an additional 157,700 shares during the last quarter.

Key Stories Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: New analyses from the Phase 3 ACACIA-HCM study showed aficamten improved exercise-capacity measures and benefited multiple responder groups in patients with non-obstructive hypertrophic cardiomyopathy. The results also supported the drug’s dose-adjustment strategy and safety profile, potentially strengthening its regulatory and commercial prospects. ACACIA-HCM additional data
• Positive Sentiment: Market coverage has renewed attention on Cytokinetics’ heart-drug pipeline, with commentary suggesting aficamten’s multi-domain benefits could improve the company’s long-term growth and valuation potential. Analysts maintain a broadly favorable view, with 18 Buy ratings, one Hold and one Sell, and an average price target of $106.06—well above recent trading levels. Analyst price target coverage
• Neutral Sentiment: Chief Executive Officer Robert Blum sold 7,500 shares for approximately $471,600 under a pre-arranged Rule 10b5-1 trading plan. He retained 278,544 shares, so the transaction represents only a 2.62% reduction in his direct holdings and is a limited signal of management sentiment. SEC Form 4 filing
• Negative Sentiment: Cytokinetics remains unprofitable, with analysts expecting a full-year loss of approximately $5.98 per share. Recent quarterly revenue also declined year over year, leaving investors focused on the timing of aficamten’s potential approval and commercialization.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that improve muscle function. The company applies muscle biology and molecular pharmacology to develop therapies for cardiovascular and neuromuscular diseases in which impaired muscle performance contributes to disease progression or disability.

Its lead programs include aficamten, a next-generation cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy, and other investigational compounds designed to modulate the activity of cardiac or skeletal muscle.